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ABSTRACT
Neuroendocrine tumors develop from any part of the gastrointestinal tract. Duodenal neuroendocrine tumors constitute only 2.6% of 
all neuroendocrine tumors. Somatostatinomas are a type of neuroendocrine tumor. They are more common in the pancreas. We present 
a rare case of duodenal somatostatinoma. A 53-year-old male was presented with a complaint of upper abdominal pain. On evaluation, 
multi detector computed tomography showed heterogeneously enhancing hypodense mass in the medial wall of the second part of 
duodenum and head of pancreas measuring 3.1 × 2.8 cm. Whipples surgery was done and the microscopy showed neuroendocrine 
tumor with psammomatous calcification. On immunohistochemistry evaluation, the tumor cells were positive for Chromogranin, 
Synaptophysin, and Somatostatin. Hence, we reported this case as duodenal somatostatinoma.
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Neuroendocrine tumors are tumors derived from neuroendocrine cells that can develop from any part of the gastrointestinal tract. They can be broadly 
classified into functional and non- functional tumors based 
on their symptoms [1]. They can occur sporadically or as a 
result of hereditary predisposition syndromes such as multiple 
endocrine neoplasia type-1[MEN-1], Von-Hippel-Lindau’s 
disease or neurofibromatosis type-1. Duodenal well-differentiated 
neuroendocrine tumors account for only 2.6% of all neuroendocrine 
tumors [2]. Somatostatin-producing neuroendocrine tumor of the 
duodenum constitute 18-21% of the neuroendocrine tumors [18]. 
Somatostatinomas are derived from somatostatin producing 
delta cells of the pancreas or from endocrine cells of digestive 
tract [3,4]. Pancreas is the most common site of somatostatinoma 
(68%), followed by the duodenum (19%), ampulla of vater 
(3%) and small intestine (3%) [5]. Somatostatinomas are 
malignant tumors that develop lymphnode or liver metastasis at 
the time of diagnosis [6]. Here, we present a case of duodenal 
somatostatinoma which was incidentally diagnosed in a patient 
who came for laparoscopic cholecystectomy.
CASE REPORT
A 53-year-old male was presented with complaints of upper 
abdominal pain for one month. On general examination, the 
patient was found to have gall bladder calculi. The patient was 
referred to our hospital for laparoscopic cholecystectomy. On 
examination, the patient was afebrile, with absensce of jaundice 
and anemia and had no generalized lymphadenopathy. His vitals 
were stable while the per abdomen was soft and non-tender. 
On further evaluation, his ultrasound of the abdomen showed 
an irregular hypoechoic mass in the head of the pancreas measuring 
3.7 × 2.8 cm with edematous duodenum. Also, there were few 
hyperechoic lesions in the liver and chronic cholecystitis. Multi 
detector computed tomography (MDCT) showed heterogeneously 
enhancing hypodense mass in the medial wall of the second part of 
duodenum and head of pancreas measuring 3.1 × 2.8 cm. Magnetic 
resonance imaging (MRI ) showed duodenal wall thickening with 
infiltration of the head of the pancreas. Other lab investigations 
showed serum bilirubin 0.4mg/dl, Serum glutamic oxaloacetic 
transaminase (SGOT) -23U/L, Serum glutamic pyruvic transaminase 
Figure 1: Endoscopic ultrasound guided FNAC from the lesion- 
acinar arrangement of neoplastic cells
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(SGPT) - 28U/L, cancer antigen (CA) 19.9-20.1U/ml, HbA1C- 
7.2%. Endoscopic ultrasound Fine needle aspiration cytology (EUS 
FNAC ) was done from the mass which showed atypical cell clusters 
with focal acinar arrangement suggestive of malignancy (Fig. 1).
A provisional diagnosis of duodenal malignancy infiltrating the 
pancreas was made and surgery was the treatment of choice. The 
patient underwent Whipples surgery. Intraoperatively, there was a 
growth in D2 involving the head of the pancreas. Hepatoduodenal 
lymphnodes were enlarged. Uncinate process of the pancreas was 
adherent to the superior mesenteric artery. Cholelithiasis (multiple 
calculi) were found; one liver nodule measuring 3 cm was found. 
Frozen section biopsy was done which was negative for malignancy.
Gross examination of the specimen showed an ill defined 
mass measuring 4×3×2 cm in the second part of duodenum 
infiltrating the head of the pancreas. Mass was 0.5 cm proximal 
to the ampulla. All the resection margins, ampulla and bile duct 
were free of tumor infiltration. The microscopic examination 
showed that the tumor cells were arranged in nests and pseudo 
acinar pattern (Fig. 2). The cells were uniform with finely granular 
chromatin (Fig. 3). Psammoma bodies were found (Fig. 4). 
On Immunohistochemistry evaluation, the neoplastic cells 
stained positive for chromogranin, synaptophysin and somatostatin 
(Fig. 5). Ki-67 labeling index was 7% hence we diagnosed it as 
Grade 2 well differentiated neuroendocrine tumor, primary duodenal 
somatostatinoma with infiltration into the pancreas and lymph 
node metastasis P (T3N1). At 6 month and one-year follow-up, 
abdominopelvic computed tomography showed no recurrent mass.
DISCUSSION
Somatostatinoma is a rare gastroenteropancreatic (GEP) endocrine 
tumor with an annual incidence of 1 in 4 million [7] and the median 
age is 54 years (range 24-84years) [8]. Somatostatin is a cyclic 
tetradecapeptide, widely distributed in normal human tissues 
and secreted by the hypothalamus, cerebrum, spinal cord, vagus 
nerve, delta cells in Langerhans islets of the pancreas, stomach, 
duodenum, and small intestine [9]. Somatostatin classified as the 
inhibitory hormone has an inhibitory effect on insulin, glucagon, 
gastrin, secretin, somatotrophin, thyrotropin, gastric inhibitory 
peptide, vasoactive intestinal peptide (VIP), growth hormone, 
thyroid stimulating hormone (TSH) and prolactin. This inhibitory 
effect of somatostatin leads to somatostatin syndrome also called 
as an inhibitory syndrome which consists of diabetes mellitus, 
diarrhea/steatorrhea, and cholelithiasis. 
The somatostatin syndrome is more common in pancreatic 
somatostatinomas due to high levels of somatostatin secreted 
by these pancreatic tumors [10,11,12]. Our patient presented 
with diabetes mellitus and cholelithiasis which are the 
major manifestations of the inhibitory syndrome. Duodenal 
somatostatinomas are identified earlier than pancreatic counterparts 
because they are presented with abdominal pain, obstructive 
jaundice, cholelithiasis, vomiting, and abdominal bleeding [13].
Most somatostatinomas are incidentally diagnosed like in our 
case, where the patient had abdominal pain and while evaluating 
for cholelithiasis duodenal mass, infiltrating the pancreas was 
diagnosed. Computerized Tomography (CT), MRI, selective 
Figure 2: Low power view- H&E(Hematoxylin and Eosin) 
neoplastic cells arranged in nests
Figure 3: High power view- H&E stain shows psammomatous 
calcification
Figure 5: (a) IHC shows synaptophysin positivity. (b) IHC shows Chromogranin positivity. (c) IHC shows Somatostatin positivity.
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arteriography of the celiac tripod and endoscopic retrograde 
cholangiopancreatography (ERCP) are useful diagnostic 
modalities for identifying the tumor [14]. 
On gross examination, somatostatinomas arising from the 
gastrointestinal tract are submucosal lesions with exophytic 
growth which can ulcerate or bleed. Pancreatic tumors are 
well circumscribed, grey-white to yellow tan nodule [15]. 
Duodenal somatostatinomas are smaller than pancreatic lesions. 
Histopathologic features of these tumors are similar to other 
neuroendocrine tumors. The neoplastic cells are arranged in 
nests, trebaculae or acinar pattern. Fewer mitotic figures are 
seen with little necrosis [16]. The most characteristic feature of 
somatostatinoma is the psammoma bodies [13]. 
Immunohistochemically, neuroendocrine tumors are 
positive for synaptophysin, chromogranin, and CD-56. 
Immunohistochemistry for somatostatin is positive in 
somatostatinomas [8]. Based on the mitotic rate or Ki-67 index 
neuroendocrine tumors are graded in WHO 2010 classification 
[18] (Table1). Adenocarcinoma is a close differential diagnosis 
for somatostatinoma. However, adenocarcinoma is negative 
for chromogranin, synaptophysin, and somatostatin. Kim JA 
et al reported a similar case of 58-year-old male with duodenal 
submucosal mass abutting the ampulla. Whipples surgery 
was done and on IHC evaluation the tumor cells stained for 
chromogranin, synaptophysin and somatostatin. After the 6 
months follow up, the patient had no recurrent mass [21].
There is controversy regarding the role of surgery for duodenal 
NET between 10 and 20mm size. It is widely accepted that 
surgery is the treatment of choice for tumors >20mm in size [2]. 
Independent risk factors for primary tumor metastasis are invasion 
of muscularispropria, size >20mm and presence of mitotic 
figures [19]. Adjuvant chemotherapy for somatostatinomas is not 
recommended. In case of locally advanced disease or widespread 
metastasis tumordebulking, chemoembolization of the primary 
tumor and of hepatic metastasis, chemotherapy, somatostatin 
receptor (SSTR)- analogs (octreotide), and IFN-α can be used to 
control the clinical symptoms [20].
CONCLUSION
Good clinical evaluation and preoperative workup is the most 
important step in medical practice. A patient with abdominal pain 
and symptoms of cholelithiasis by proper evaluation found to 
have duodenal mass with pancreatic infiltration and ended up with 
Whipples operation. Hence the history which we elicit from the 
patient is just a tip of the iceberg. Only by thorough evaluation, 
we will be able to identify the rarest tumor which is hiding inside.
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Table 1 - Recommended grading system for well differentiated 
gastroenteropancreatic neuroendocrine tumors
Grade Mitotic rate  
(per 2mm2)
Ki-67 index 
(%)
Well differentiated 
neuroendocrine tumor Grade1
<2 <3
Well differentiated 
neuroendocrine tumor Grade2
2-20 3-20
Well differentiated 
neuroendocrine tumor Grade3
>20 >20
